ALVERSTONE
GROUP OF COMPANIES

Alverstone
Drug House (P) Ltd
MAINTAIN CURE
ISO 9001:2015 CERTIFIED COMPANY

ALVERSTONE IHED LLC
Global Pharmaceutical Company
Dubai, United Arab Emirates

ALVERSTONE DRUG HOUSE PVT LTD

BIO 360 KERALA LIFE SCIENCES INDUSTRIES PARK,
THONNAKKAL, THIRUVANANTHAPURAM - 695317

CONTACT NO: +91 81398 07686, +91 97463 97686(IND)
+971 0547 401 777, +971 5457 62020 (UAE)

mail@alverstone.in www.alverstoneglobal.com

Fastest Growing Pharmaceutical Company

BUSINESS
PLAN & PROPOSAL

EXECUTIVE SUMMARY

At Alverstone Drug House, we are committed to ensuring access to high-quality, affordable medicines for patients in need. Built on the guiding principle of "Caring for Life," we have established ourselves as a trusted partner in the healthcare industry. Our humanitarian approach and deep-rooted community connections drive us to create a healthier future through innovative solutions and unwavering dedication. Since our inception in 2020, we have rapidly grown into one of Kerala's most reliable pharmaceutical companies, expanding our reach across South India. Specializing in critical care and cardiac care injectables, our high-quality, affordable products have earned the trust of healthcare providers and patients alike. By consistently delivering reliable and cost-effective solutions, we have cemented our reputation as a leader in the pharmaceutical industry.

With a forward-thinking approach, we prioritize research, product expansion, and advanced manufacturing. Our vision includes establishing world-class production facilities, fostering innovation, and maintaining the highest standards of quality and ethics. A highly skilled workforce and collaborative culture ensure operational excellence, driving our progress toward transformative healthcare solutions.

Our presence spans across South India, serving over 1,800 hospitals and 12,000 doctors in various specialties, including surgery, orthopaedics, gynaecology, cardiology, nephrology, and general medicine. By offering high-quality medicines at accessible prices, we reinforce our commitment to improving healthcare outcomes. Emphasizing efficiency and discipline, we continuously innovate to address the evolving needs of healthcare providers and patients.

The pharmaceutical supply chain in Kerala faces significant challenges, with high transportation costs inflating medicine prices. To combat these issues, we are regionalizing production through our advanced manufacturing facility, improving accessibility and affordability. This initiative positions us as a key player in strengthening Kerala's pharmaceutical infrastructure.

While competition exists from regional and multinational corporations, our focus on critical care injectables and in-house production ensures a cost-effective, responsive supply chain. By maintaining compliance with stringent regulatory standards, we enhance product safety and reliability, further strengthening our market position. Growing consumer awareness of domestic manufactured medicines offers us a distinct advantage in Kerala's evolving healthcare landscape. Innovation remains at the core of our growth strategy. Byinvesting in advanced technologies and exploring new healthcare trends, we stay ahead in an ever-changing industry.

Sustainability is integral to our mission, as we optimize resources, minimize environmental impact, and create long-term value for stakeholders. Looking ahead, Alverstone Drug House is set for significant expansion, introducing branded products in new markets and launching retail pharmacy operations under "Alverstone Pharmacy." Our diverse portfolio will include allopathic medicines, herbal cosmetics, childcare solutions, dietary supplements, and more. By evolving with market demands, we aim to extend our reach and uphold our commitment to high-quality, affordable healthcare solutions.

Our journey is defined by care, commitment, and progress, as we continue to impact the healthcare ecosystem positively. With a steadfast focus on innovation and accessibility, we are building a healthier future for communities across Kerala, South India, and beyond.

CORE LEADERSHIP

Mananging Director
Rijas Rehman

"We must consider not just the needs of individual patients but also the collective health of our communities"

Director
Muhammed Uvaiz N

"Study with intensity before starting, and you're on the wayz refuse to surrender to obstacles"

VISION

Our Vision to be become a valuable global pharmaceutical company by continuously researching, Developing and manufacturing a wide range of pharmaceutical products complying with high regulatory standards. To deliver affordable branded medicines for a healthier future.

UAE PHARMA TRENDS

The United Arab Emirates government is actively focused on developing technology and advancement in the pharmaceutical industry. Several initiatives were taken within the country like Dubai Industrial Strategy 2030 and Abu Dhabi Vision 2030 are focused towards developing the pharmaceutical industry due to its future growth prospects, export potential and midterm to long-term economic impact. In recent years, majorly the pharmaceutical demands were fulfilled by imported drugs and products. Therefore, the market players are increasing their manufacturing of pharmaceutical products, thereby initiating strengthening bonds with multinational market players. The government is preparing favourable schemes and plans for the distribution channels and funding strategic locations and sophisticated logistics infrastructure to further strengthen the growth of the UAE pharmaceutical market in the future five years.

Government Initiatives

The UAE's government's initiatives to increase and improve healthcare access will be aided by rising support from the business sector. The National Unified Medical Record system and the Public Health Management platform, both aim to use digital health solutions to foster collaboration between the public and private sectors while promoting and monitoring public health initiatives, and improving the overall provision of healthcare, that has been introduced by the UAE's Ministry of Health and Prevention over the course of 2021. According to the International Diabetes Federation, in 2021, out of 1000s, about 990 Emiratis were suffering from diabetes. Additionally, the growing research and development activities in the pharmaceutical industry are projected to augment the growth of the UAE pharmaceutical market in the forthcoming years.

DOMESTIC MARKET - UAE

Pharmaceutical sales reached USD 3.5 billion in 2020. The UAE's pharmaceutical sales have been growing at a CAGR of 7 per cent over 2017-2020. In 2021, pharmaceutical spending is expected to reach USD 3.7 billion. The UAE exported USD 1.1 billion worth of pharmaceutical products in 2020.

The UAE pharma market is projected to be worth $4.7 billion by 2025.

UAE HEALTH INDEX



The United Arab Emirates (UAE) is a rapidly developing country composed of a multinational population with varying educational backgrounds, religious beliefs, and cultural practices, which poses a challenge for population based public health strategies. A number of public health issues significantly contribute to morbidity and mortality in the UAE. The findings of a panel of medical and public health specialists from UAE University and various government health agencies commissioned to report on the health status of the UAE population. Over 60% of the population is overweight, 20% of the population has been diagnosed with diabetes and a further 18% is considered at risk of develoing diabetes, and cardiovascular diseases accouned for 38% of all mortality

The panel reviewed and evaluated all available evidence to list and rank (1=highest priority) the top four main public health issues:

1)cardiovascular disease accounted for more than 25% of deaths in 2020
2) Injury caused 17% of mortality for all age groups in 2020'
3) Cancer accounted for 10% of all deaths in 2010, and the incidence of all cancers is projected to double by 2020.

ALVERSTONE IHED LLC

Capturing the market potential of the UAE pharma industry, Kerala's fastest-growing pharmaceutical company Alverstone Drug House (P) Ltd is gearing up to establish its international presence on Arabian soil.

We are excited to present a proposal outlining the strategic steps and considerations for successfully entering the international market. Our company has extensive experience in the pharma business and can provide the expertise and support necessary to ensure a smooth and profitable entry into new territories.

1. Market Research and Analysis
2. Market Entry Strategy
3. Legal and Regulatory Compliance
4. Localization and Adaptation
5. Distribution and Logistics
6. Market Penetration and Promotion
7. Risk Assessment and Mitigation
8. Performance Measurement and Adaptation

The plan encourages the sale of company-branded products to enhance market presence. Alverstone Pharmacy will be set up to increase customer awareness. It will offer different services and drugs. Through the combination of branded products and pharmacy services, the company seeks to enhance customer loyalty and access to healthcare. The emphasis is on creating a trusted community brand.

1. Allopathic Medicine (Cardio Diabetics & Critical Care Products)
2. Cosmetic and Fragrance Products (Herbal)
3. Childcare
4. Disinfection product
5. Feminine care product
6. Parental care product
7. Dietary supplements containing multivitamins and minerals

The process of choosing the appropriate product is undertaken with the utmost degree of careful attention and deep insight into detail, ensuring that every single detail pertinent to the choice is carefully assessed and considered. This thorough process entails undertaking thorough surveys of the products, as well as undertaking rigorous marketing research studies, both of which are undertaken under the watchful eye and expert guidance of highly experienced and skilled marketing experts who have a vast amount of knowledge and experience in the field. Along with these critical processes, a thorough and strategic business plan has been carefully developed, with the main objective of greatly increasing the company's presence and influence within a relatively short period of time. This aggressive growth plan will be made possible through the establishment of partnerships and collaborative agreements with top insurance firms based in the UAE, accomplished through the use of innovative and effective promotional strategies coupled with creative marketing ideas that excel for their excellence in the competitive market.

The company has its eyes set on launching its operations within the Arab world by establishing a clearly defined and carefully structured plan that aims to achieve an impressive revenue goal of 67 million dirhams within a short period of just 5 years. This aggressive goal is not only a significant challenge but also a testament to the strong vision and unrelenting determination that characterize their thorough business strategy, reflecting their strong commitment to attaining growth and success within this highly competitive market environment.

OUR JOURNEY

ALVERSTONE IHED LLC
Global Pharmaceutical Company
Dubai, United Arab Emirates

Unveiling lovely you
Ruby
DE PARIS
keep

Alverstone
Drug House (P) Ltd
MAINTAIN CURE
ISO 9001:2015 CERTIFIED COMPANY

GOVERNMENT OF INDIA
MINISTRY OF CORPORATE AFFAIRS
Certificate of Incorporation

alverstone.in

Alverstone
Drug House (P) Ltd
MAINTAIN CURE
ISO 9001:2015 CERTIFIED COMPANY

OVERVIEW

1. **Established in October 2020,** emerging as a leading pharmaceutical company.
2. **ISO 9001:2015 Certified,** ensurin high-quality standards.
3. Product Portfolio: **60+ critical care products** (injections & tablets).
4. Healthcare Reach: **Trusted by 1200+ doctors, 600 hospitals, and 700 chemists.**
5. Expansion: Started in **South Kerala**, now operating in **Tamil Nadu, Andhra Pradesh, Karnataka, and Telangana.**

ALVERSTONE LLC
Global Pharmaceutical Company
Dubai, United Arab Emirates

OVERVIEW

1. 2024: Opened **Dubai corporate office** for **global business and UAE expansion.**
2. 2024: Strengthening **South India** operations and **expanding into GCC, European, and African markets.**
3. **Upcoming Projects:**
   Stage I: Advanced AIM Plant (Injectable Division).
   Stage II: Marketing Expansion in GCC, Kenya & Georgia.

Investment Meet-up August 2020

The remarkable journey of Alverstone Drug House (P) Ltd, a company born amidst the challenges of the 2020 pademic. Despite a difficult economic climate, we secured crucial seed funding from a group of visionary investors in 2020. With their support, we have navigated a dynamic market environment, achieved significant milestones, and positioned ourselves for continued growth. Alverstone Drug House (P) Ltd was founded in 2020 with the vision of owning a Pharmaceutical Manufacturing Plant. Recognizing the potential of higher demand for pharmaceuticals, we embarked on this journey with a passionate team and a clear mission. Securing online funding of 5,000,000 five million Rupees from a distinguished group of investors, including was a pivotal moment. Their confidence in our vision provided the critical resources needed to launch and establish ourselves.

Head Office

October 2020 @Trivandrum

Our Head office the vibrant hub where our team collaborates, creates, and drives to our Mission. Located in Chempakamangalam near Bio 360 Life Science Park our office reflects our commitment to Company Values, e.g., innovation, and creativity.

At Alverstone Drug House (P) Ltd we believe in the power of collaboration. Our office layout encourages interaction and teamwork, fostering a sense of community among our employees. Our office is designed to foster a dynamic and inspiring work environment



OUR NEW PRODUCTS

ALFE SP
Aceclofenac 100 mg + Paracetamol 325 mg +
Serratiopeptidase Tablet 15 mg

MC ZOLE 40T
Pantaprazole Tablet IP 40 mg

MC ZOLE DC 40
Pantoprazole Gastro-Resistant 40 mg +
Domperidone Prolonged-Release Capsule IP 30 mg

COCYT COUGH SYRUP
Levosalbutamol Sulphate 1 mg +
Ambroxol Hydrochloride 30 mg + Guaiphenesin 50 mg

MC PAIN Gel — Arthritis Pain Reliever
Diclofenac Diethylamine 1.16% + Methyl Salicylate 10%
Linseed Oil 3% + Menthol Gel 5%

DILLUX D3 Nano Shot
Vitamin D3 Oral Solution 60,000 I.U.

Feels COUGH SYRUP
Dextromethorphan Hydrobromide 10 mg +
Phenylephrine Hydrochloride 5 mg+
Chlorpheniramine Maleate Syrup 2 mg

alverstone.in

ALL PRODUCT LIST

MC NOX - 40mg
Enoxaparin Sodium Injection IP 40mg/0.4ml

MC THROCYN 500
Azithromycin Tablets IP 500 mg

ALVIRON - 100mg
Iron Sucrose Injection USP IP 100mg / 5ml

ALVECORT 6
Deflazacort Tablets 6 mg

ALFE T - 100
Aceclofenac & Thiocolchicoside Tablets

MC ZOLE - 40mg
Pantoprazole 40mg for injection BP

MC TAZ - 4.5gm
Piperacillin 4g & Tazobactam 500mg

ALFE P - 100
Aceclofenac 100mg & Paracetamol 325mg

LEVAS - M 10
Montelukast Sodium 10mg &
Levocetirizine Hydrochloride 5mgTablets IP

alverstone.in

LAUNCH MEET & Training



QUALITY MANAGEMENT SYSTEM

Certificate of Registration

ROHS

This is to Certify That The Quality Management System of

Alverstone

ALVERSTONE DRUG HOUSE PRIVATE LIMITED

3/133 C, AK BUILDING, CHEMPAKAMANGALAM, THONNAKKAL
P.O., TRIVANDRUM - 695 104, KERALA, INDIA.

has been assessed and found to conform to the requirements of

ISO 9001:2015

for the following scope :

MARKETING OF ALLOPATHIC MEDICINES IN THE FORM OF TABLETS, CAPSULES, DRY SYRUPS, OINTMENT, GEL, SACHET, INJECTABLES AND COSMETICS.

Certificate No	23DQLB19		
Initial Registration Date	: 11/07/2023	Issuance Date	: 11/07/2023
Date of Expiry*	: 10/07/2026		
1st Surve. Due	: 11/06/2024	2nd Surve. Due	: 11/06/2025

DIRECTOR
ROHS Certification Pvt. Ltd.

IAF eiac CB-QMS-035



GOVERNMENT OF INDIA
MINISTRY OF CORPORATE AFFAIRS
Central Registration Centre

Certificate of Incorporation

[Pursuant to sub-section (2) of section 7 and sub-section (1) of section 8 of the Companies Act, 2013 (18 of 2013) and rule 18 of the Companies (Incorporation) Rules, 2014]

I hereby certify that ALVERSTONE DRUG HOUSE PRIVATE LIMITED is incorporated on this Eighth day of October Two thousand twenty under the Companies Act, 2013 (18 of 2013) and that the company is limited by shares.

The Corporate Identity Number of the company is U51909KL2020PTC064881.

The Permanent Account Number (PAN) of the company is **AAUCA1681Q** *

The Tax Deduction and Collection Account Number (TAN) of the company is **TVDA03317G** *

Given under my hand at Manesar this Eighth day of October Two thousand twenty .

Digital Signature Certificate
Mr. Pankaj Srivastava
ASST. REGISTRAR OF COMPANIES
For and on behalf of the Jurisdictional Registrar of Companies
Registrar of Companies
Central Registration Centre

Disclaimer: This certificate only evidences incorporation of the company on the basis of documents and declarations of the applicant(s). This certificate is neither a license nor permission to conduct business or solicit deposits or funds from public. Permission of sector regulator is necessary wherever required. Registration status and other details of the company can be verified on www.mca.gov.in

Mailing Address as per record available in Registrar of Companies office:

ALVERSTONE DRUG HOUSE PRIVATE LIMITED
MP III/133 C, A K Building, Mangalapuram, Trivandrum,
Thiruvananthapuram, Kerala, India, 695104

* as issued by the Income Tax Department



FORM 21 B
[See rule 61(2)]
[LICENCE TO SELL, STOCK OR EXHIBIT OR OFFER FOR SALE, OR DISTRIBUTE] BY WHOLESALE DRUGS SPECIFIED IN SCHEDULES C AND C(1) [EXCLUDING THOSE SPECIFIED IN SCHEDULE X]

RIJAS A

1. RIJAS A (KALLUVILA VEEDU , KOTTAMKARA, NEAR GHSS KERALAPURAM, CHANDHANATHOPE P.O PERINAD ,KOLLAM 691014)
DIRECTOR(s) of ALVERSTONE DRUG HOUSE PRIVATE LIMITED
is hereby licensed to sell, stock, or exhibit (or offer) for sale, or distribute by wholesale on the premises situated at
DOOR NO. MP. 3/133C, FIRST FLOOR,
A.K.BUILDING, CHEMPAKAMANGALAM, THONNAKKAL-P.O , TRIVANDRUM
Tal : THIRUVANANTHAPURAM (THIRUVANANTHAPURAM)
Pin : 695104 Phone: Mobile: 9656107686
the following category of the drugs specified in Schedules C and C(1) [excluding those specified in Sch. X] to the Drugs and Cosmetics Rules, 1945.
Categories of Drugs : All items of schedule C and C1(i) drugs,[excluding those specified in Sch. X]
2.The licence shall be in force from : 22.Dec-2020 to 21.Dec-2025 Area : 94.01 SqMts
2-a.The sale shall be made under the personal supervision of a competent person :
RP-68322 - MEREESHA MENDEZ(DPH,)
3.This licence is subject to the conditions stated below and to the provisions of the Drugs and Cosmetics Act, 1940, and the Rules thereunder.
4.Specific Condition: BLOOD BAGS ARE NOT PERMITTED

e-Signed on 22/12/2020 13:49:12
TPAV # FCYSQHH895

SAJEEV KUMAR M S
Licensing Authority
Drugs Control Department

Licence no: KL-TVM-156182
On: 22.Dec-2020

Conditions of Licence

1. This licence shall be displayed in a prominent place in a part of the premises open to the public.
2. The licence unless sooner suspended or cancelled, shall remain valid perpetually. However, the compliance with the conditions of licence and the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) and the Drugs and Cosmetics Rules, 1945 shall be assessed not less than once in three years or as needed as per risk based approach.
3. If the licensee wants to sell, stock or exhibit for sale, or distribute, during the currency of the licence, additional categories of drugs listed in schedules C and C (1) [excluding those specified in Sch.X] but not included in this licence, he should apply to the Licensing Authority for necessary permission.This licence will be deemed to extend to the categories of drugs in respect of which such permission given.
This permission shall be endorsed on the licence by the Licensing Authority.
4. (i) No drug shall be sold unless such drug is purchased under a cash or credit memo from a duly licensed dealer or a duly licensed manufacturer.
(ii) No sale of any drug shall be made for purposes of resale to a person not holding the requisite licence to sell, stock or exhibit for sale or distribute the drug;
Provided that this condition shall not apply to the sale of any drug to—
(a) an officer or authority purchasing on behalf of Government, or
(b) a hospital, medical, educational or research institution or a registered medical practitioner for the purpose of supply to his patients, or
(c) a manufacturer of hydrogenated vegetable oils, beverages, confectionaries and other non-medicinal products, where such drugs are required for processing these products;
5. Omitted.
6. The licensee shall inform the Licensing Authority in writing in the event of any change in the constitution of the firm operating under the licence. Where any change in the constitution of the firm takes place, the current licence shall be deemed to be valid for a maximum period of three months from the date on which the change take place unless, in the meantime, a fresh licence has been taken from the Licensing Authority in the name of the firm with the changed constitution.
7. The Licensee shall not Claim any equities or rights in the property under reference on strength of this licence.

Note: Prev Dtls - 41447--ALVERSTONE DRUG HOUSE PRIVATE LIMITED--RIJAS.A (MANAGING DIRECTOR)--DOOR NO. MP. 3/133C, FIRST FLOOR,--A.K.BUILDING,

This License/Certificate is eSIGNED. Physical Signature is NOT Required

District	Dept File No	Type/Fresh License	Form [21B] Licence No	Old LIC No
THIRUVANANTHAPURAM	41447	FRE--347250-13/11/2020	KL-TVM-156182	-

For online Third Party Approval Verification; Go to xlnindia.gov.in & Click TPAV button. 22/12/20



FORM 20B
[See rule 61(1)]
[LICENCE TO SELL, STOCK OR EXHIBIT OR OFFER FOR SALE, OR DISTRIBUTE] BY WHOLESALE, DRUGS OTHER THAN THOSE SPECIFIED IN [SCHEDULES C, C(1) AND X]

RIJAS A

1. RIJAS A (KALLUVILA VEEDU , KOTTAMKARA, NEAR GHSS KERALAPURAM, CHANDHANATHOPE P.O PERINAD ,KOLLAM 691014)
DIRECTOR(s) of ALVERSTONE DRUG HOUSE PRIVATE LIMITED
is hereby licensed to sell, stock, or exhibit (or offer) for sale, or distribute by wholesale drugs other than those specified in [Schedules C,C(1) and X] on the premises situated at
DOOR NO. MP. 3/133C, FIRST FLOOR,
A.K.BUILDING, CHEMPAKAMANGALAM, THONNAKKAL-P.O , TRIVANDRUM
Tal : THIRUVANANTHAPURAM (THIRUVANANTHAPURAM)
Pin : 695104 Phone: Mobile: 9656107686
subject to the conditions specified below and to the provisions of the Drugs and Cosmetics Act, 1940 and the Rules thereunder.
2.The licence shall be in force from : 22.Dec-2020 to 21.Dec-2025 Area : 94.01 SqMts
3.The sale shall be made under the personal supervision of a competent person :
RP-68322 - MEREESHA MENDEZ(DPH,)
4.Categories of Drugs : Drugs covered under the license
5.Specific Condition: TINCTURES FOR INTERNAL USE ARE NOT PERMITTED

e-Signed on 22/12/2020 13:49:12
TPAV # FCYSQHH895

SAJEEV KUMAR M S
Licensing Authority
Drugs Control Department

Licence No: KL-TVM-156181
On: 22.Dec-2020

Conditions of Licence

1. This licence shall be displayed in a prominent place in a part of the premises open to the public.
2. The licence unless sooner suspended or cancelled, shall remain valid perpetually. However, the compliance with the conditions of licence and the provisions of the Drugs and Cosmetics Act, 1940 (23 of 1940) and the Drugs and Cosmetics Rules, 1945 shall be assessed not less than once in three years or as needed as per risk based approach.
3. (i) No drug shall be sold unless such drug is purchased under a cash or credit memo from a duly licensed dealer or a duly licensed manufacturer.
(ii) No sale of any drug shall be made to a person not holding the requisite licence to sell, stock or exhibit for sale or distribute the drug. Provided that the condition shall not apply to the sale of any drug to—
(a) an officer or authority purchasing on behalf of Government, or
(b) a hospital, medical, educational or research institution or a registered medical practitioner for the purpose of supply to his patients, or
(c) a manufacturer of beverages, confectionaries biscuits and other non-medicinal products, where such drugs are required for processing these products;
4. Omitted.
5. The licensee shall inform the Licensing Authority in writing in the event of any change in the constitution of the firm operating under the licence.Where any change in the constitution of the firm takes place, the current licence shall be deemed to be valid for a maximum period of three months from the date on which the change take place unless, in the meantime, a fresh licence has been taken from the Licensing authority in the name of the firm with the changed constitution.
6. The Licensee shall not Claim any equities or rights in the property under reference on strength of this licence.

Note: Prev Dtls - 41447--ALVERSTONE DRUG HOUSE PRIVATE LIMITED--RIJAS.A (MANAGING DIRECTOR)--DOOR NO. MP. 3/133C, FIRST FLOOR,--A.K.BUILDING, CHEMPAKAMANGALAM, THONNAKKAL-P.O--TRIVANDRUM--695104--Private Limited

This License/Certificate is eSIGNED. Physical Signature is NOT Required

District	Dept File No	Type/Fresh License	Form [20B] Licence No	Old LIC No
THIRUVANANTHAPURAM	41447	FRE--347250-13/11/2020	KL-TVM-156181	-

For online Third Party Approval Verification; Go to xlnindia.gov.in & Click TPAV button. 22/12/20

Our Manufactures

HEALTH BIOTECH LIMITED Health For All
Broad Injectables
VR VAQURE REMEDIES
PROTECH TELELINKS A WHO-GMP Certified Co.

Associated with

CROWNE PLAZA HOTELS & RESORTS
NOVOTEL HOTELS, SUITES & RESORTS

alverstone.in

INAGURATED BY

State Film award winner Thanmaya sol

CPHI Expo

Largest Pharma Expo @Delhi,India

ABD Expo

Largest CHINA trade Expo @DUBAI



ARAB HEALTH Expo

Largest ARAB Health Expo @DUBAI



UAE Expansion

Online meet up for the investment of South india expansion
36 participants attend this online meet up



ENTERING
UAE
Pharma sector









alverstone.in



UAE
Corporate Office
Inauguration

ALVERSTONE

INVESTMENT IN HEALTHCARE ENTERPRISES AND DEVELOPMENT LLC

Global Expansion

alverstone.in



alverstone.in

alverstone.in

Kuly
DE PARIS
Niacinamide 5%
BODY LOTION
SPAIN
5 نياسيناميد%
مستحضرات الجسم
إسبانيا
Kuly Body Lotion
RADIANT SILKY BODY LOTION
NIACINAMIDE + VITAMIN C
CLEANSE AND GLOW
PRO VITAMIN B5 /VEGA
AED/52

Kuly Face mask

- BRIGHTENING CLEANSER
- DARK SPOT - SENSITIVE SKIN
- CERAMIDES & SALICYLIC ACID
- CHARCOAL BLACK

AED/41

Kuly Glutathione serum
GLUTATHIONE 2% & VITAMIN C .82%
ANTI PIGMENTATION SERUM
FOR FLAWLESS RADIANCE
GENTLE BRIGHT TECHNOLOGY
AED/52

alverstone.in

Kuly Moisturising cream

- WITH ESSENCIAL 3 CERAMIDES
- HYDRONIC ACID & VITAMIN B5
- DEEP HYDRATION
- MOISTURE LOCK EXPERT

AED/52

alverstone.in

Kuly Multy Vitamin cream

- VITAMIN E & PROTOGLYCANS GEL
- ANTIOXIDATIVE
- OIL FREE MOISTURISING
- MULTYVITAMIN

AED/38

Kuly Quick whitening serum

- REDUCE PIGMENTATION & SPOT
- FERULIC ACID + HYALURONIC ACID
- PROTECTING SKIN ELASTICITY
- VITAMIN C

AED/35

alverstone.in

Kuly Suncreen Aqua gel

- SPF 50+
- HYALURONIC 1%
- FRAGRANCE FREE
- VITAMIN E

AED/60

alverstone.in

Kuly
DE PARIS
FAST ANTI AGING
&
Wrinkle free
SPAIN
SERUM
Kuly
DE PARIS
FAST ANTI AGING
&
Wrinkle free
SERUM
SPAIN
Kuly Anti aging &
wrinkle free serum
HYALURANIC ACID FLUID
NIGHT REPAIR SKIN CREAM
CERAMIDES & NIACINAMIDE CREAM
REPAIR AND SMOOTHEN WRINKLES
FOR ALL TYPE OF SKIN
AED/48

Kuly Perfume

EXPERIENCE THE BEST PERFUMES

AED/65

THE MARKET

PRODUCT SEGMENTATION

Cosmoceutical Products

Skin Care Products - General

UAE Cosmetic Market
Competitive Scenario

*Based on 1st year projections

MAJOR COMPETITORS

Premium Market Share by Company (2020)



Premium Market Share by Brand (2020)



Source: Glasgow Consulting Group analysis

Business Channels - UAE

Business Channels - India

Alverstone
Drug House (P) Ltd
MAINTAIN CURE
ALVERSTONE DRUG HOUSE PVT LTD

Company Portfolio

Company Name : **Alverstone Drug House (P) Ltd**
Type of Business : Pharmaceuticals Production and Marketing
Date of incorporation : Oct 2020
Area of Business : South India
Sister Concern : Alverstone IHDE LLC Dubai

Investment Details

Project : **South India Expansion**
Total Budget : Rs. 50,000,000.00 (Five Crore Rupees)
Share Value : Rs. 80.00
Percentage of Share : 49% (Forty-nine percentage)
Issued Share : 625,000 nos
1% of Share Rate : 1,020,408.00 (Ten lakh twenty thousand and four hundred rupees only)
Minimum Investment : 100,000.00 (One Lakhs)
Percentage : 0.1%

INVESTMENT SCHEME

Scheme 1

Investor	
Minimum Investment	: Rs. 100,000.00 (One Lakhs rupees)
Return on Investment (ROI)	: 4% Principal Amount (Monthly)
Period of Investment	: 30 months
Security of Investment	: Legal Documentation & Security cheques

Scheme 2

Shareholder	
Minimum Investment	: 100,000.00 (One Lakh rupees)
Return on Investment (ROI)	: A. Annual net profit B. 3.5% of principal amount (monthly or quarterly) + Annual Net profit (outstanding amount)
Period of Investment	: Lifetime
Exit Plan	: A. Intra-company share transfers are permitted. B. Shares conveyed to a new owner
Documents Given	: MCA Registration (Ministry of corporate affairs) Share certificates

THE TEAM

Rijas Rehman

Co-Founder/Managing Director

Muhammed Uvaiz N

Co-Founder/ Director



THANK YOU

Alverstone

Investment in Healthcare Enterprises and Development LLC

director@alverstone.in

+971 545 762 020
+971 547 401 777
+971 506 899 272